BiotechTube
Crestone

Crestone

Boulder, United States· Est.
crestonepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $104M

Overview

Crestone is a private, clinical-stage biotech company pioneering novel mechanism-of-action antibacterial agents to combat serious and resistant infections. Its most advanced program, CRS3123, has demonstrated promising efficacy and safety in a Phase 2 trial for C. difficile infection, with results published in a top-tier journal. The company's broader pipeline targets significant public health threats like MRSA, VRE, and nontuberculous mycobacterial (NTM) disease, positioning it in the critical fight against antimicrobial resistance (AMR). Founded in 2015 by a team of experienced scientists, Crestone operates as a research-focused organization seeking investment and talent to advance its innovative portfolio.

Infectious DiseaseAntimicrobial Resistance

Technology Platform

Discovery and development of novel mechanism-of-action small molecule drugs for bacterial infections.

Funding History

2
Total raised:$104M
Series B$69M
Series A$35M

Opportunities

The urgent global need for novel antibiotics to combat antimicrobial resistance creates a significant market opportunity, supported by potential regulatory incentives.
Positive Phase 2 data in a top-tier journal provides strong validation for the lead asset and can attract partnership or funding interest.
The company's platform approach targeting novel mechanisms could yield multiple candidates for serious, underserved infections like NTM and drug-resistant TB.

Risk Factors

High clinical development risk remains, as Phase 2 success does not guarantee Phase 3 outcomes or regulatory approval.
As a pre-revenue company, it is dependent on external financing, and failure to secure adequate funding could halt progress.
The antibacterial market, while needed, presents commercial challenges including pricing pressure and the need for stewardship, often requiring partnership with larger pharma for successful commercialization.

Competitive Landscape

The CDI treatment space is competitive, with several approved therapies (e.g., fidaxomicin, bezlotoxumab) and other novel agents in development. The broader AMR space for Gram-positive infections is also crowded with large pharma and biotech players. Crestone's differentiation hinges on the novelty of its mechanisms of action, aiming to avoid cross-resistance with existing therapies and potentially offer improved efficacy or safety profiles.

More companies in Small Molecule Drugs →More companies in United States →